Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan

Next Previous
Search
Trial Profile

Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Japanese encephalitis vaccine (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Japanese encephalitis; Measles; Mumps; Rubella
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 11 Mar 2014 Results published in the Vaccine.
  • 28 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 25 Jan 2012 Planned End Date changed from 1 Jan 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top